Cited by 567Schizophrenia research and treatmentBipolar Disorder and TreatmentPsychiatric care and mental health services

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy: Long-term Follow-up of a 2-Year Randomized Clinical Trial

Wunderink, Lex, Nieboer, Roeline M., Wiersma, Durk, Sytema, Sjoerd, Nienhuis, Fokko J.·2013·JAMA Psychiatry

DOI 10.1001/jamapsychiatry.2013.19

Open this paper in CoChat — free account

Abstract

IMPORTANCE: Short-term outcome studies of antipsychotic dose-reduction/discontinuation strategies in patients with remitted first-episode psychosis (FEP) showed higher relapse rates but no other disadvantages compared with maintenance treatment; however, long-term effects on recovery have not been studied before. OBJECTIVE: To compare rates of recovery in patients with remitted FEP after 7 years of follow-up of a dose reduction/discontinuation (DR) vs maintenance treatment (MT) trial. DESIGN: Seven-year follow-up of a 2-year open randomized clinical trial comparing MT and DR. SETTING: One hundred twenty-eight patients participating in the original trial were recruited from 257 patients with FEP referred from October 2001 to December 2002 to 7 mental health care services in a 3.2 million-population catchment area. Of these, 111 patients refused to participate and 18 patients did not experience remission. PARTICIPANTS After 7 years, 103 patients (80.5%) of 128 patients who were included in the original trial were located and consented to follow-up assessment. INTERVENTION: After 6 months of remission, patients were randomly assigned to DR strategy or MT for 18 months. After the trial, treatment was at the discretion of the clinician. MAIN OUTCOMES AND MEASURES: Primary outcome was rate of recovery, defined as meeting the criteria of symptomatic and functional remission. Determinants of recovery were examined using logistic regression analysis; the treatment strategy (MT or DR) was controlled for baseline parameters. RESULTS: The DR patients experienced twice the recovery rate of the MT patients (40.4% vs 17.6%). Logistic regression showed an odds ratio of 3.49 (P = .01). Better DR recovery rates were related to higher functional remission rates in the DR group but were not related to symptomatic remission rates. CONCLUSIONS AND RELEVANCE: Dose reduction/discontinuation of antipsychotics during the early stages of remitted FEP shows superior long-term recovery rates compared with the rates achieved with MT. To our knowledge, this is the first study showing long-term gains of an early-course DR strategy in patients with remitted FEP. Additional studies are necessary before these results are incorporated into general practice. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN16228411.

Integrity signals

Registry

Crossref · 10.1001/jamapsychiatry.2013.19

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,350
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
Woods, S. W. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0607 · Cited by 2,056
Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.1 · Cited by 1,350
Predictors of Relapse Following Response From a First Episode of Schizophrenia or Schizoaffective Disorder
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia
Lewis, D. A., Curley, A. A., Glausier, J. R., & Volk, D. W. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.10.004 · Cited by 1,071
Neuroleptic Withdrawal in Schizophrenic Patients
Gilbert, P. L. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150005001 · Cited by 434
Guided Discontinuation Versus Maintenance Treatment in Remitted First-Episode Psychosis: Relapse Rates and Functional Outcome
Wunderink, L., Nienhuis, F. J., Sytema, S., Slooff, C. J., Knegtering, R., & Wiersma, D. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0502 · Cited by 234
Self-citation
Dopamine system dysregulation by the hippocampus: Implications for the pathophysiology and treatment of schizophrenia
Grace, A. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.011 · Cited by 225

Flagged first, then by citations

Show all 24 references

1 of the 24 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 567

Who needs antipsychotic maintenance treatment and who does not? Our need to profile and personalize the treatment of first episode psychosis
Wunderink, L. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.11.007 · Cited by 16
Clinical Characteristics of Patients With Schizophrenia Who Successfully Discontinued Antipsychotics
Tani, H., Suzuki, T., Fleischhacker, W. W., Tomita, M., Mimura, M., & Uchida, H. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000959 · Cited by 16
Functional recovery of individuals with serious mental illnesses: Development and testing of a new short instrument for routine outcome monitoring.
Swildens, W. E., Visser, E., Bähler, M., Bruggeman, R., Delespaul, P., van der Gaag, M., de Haan, L., Keet, R., Nijssen, Y. A. M., van Os, J., et al. (2018) · Psychiatric Rehabilitation Journal · doi:10.1037/prj0000320 · Cited by 17
Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study
Fountoulakis, K. Ν., Dragioti, E., Antonis, T., Wiklund, T., Atmatzidis, X., Nimatoudis, I., Thys, E., Wampers, M., Hranov, L. G., Hristova, T., et al. (2020) · CNS Spectrums · doi:10.1017/s1092852920001091 · Cited by 16
Intervention précoce pour la psychose : concepts, connaissances actuelles et orientations futures
Iyer, S. N., & MALLA, A. K. (2014) · Santé mentale au Québec · doi:10.7202/1027840ar · Cited by 16
Psychosis breakthrough on antipsychotic maintenance medication (BAMM): what can we learn?
Rubio, J. M., & Kane, J. M. (2017) · Schizophrenia · doi:10.1038/s41537-017-0039-z · Cited by 16
Five year outcomes of tapering antipsychotic drug doses in a community mental health center
Steingard, S. (2018) · Community Mental Health Journal · doi:10.1007/s10597-018-0313-1 · Cited by 15
Nationale und internationale Leitlinien zur Schizophrenie
Hasan, A., Wobrock, T., Gäebel, W., Janssen, B., Zielasek, J., & Falkai, P. (2013) · Der Nervenarzt · doi:10.1007/s00115-013-3913-6 · Cited by 15
Is schizophrenia disappearing? The rise and fall of the diagnosis of functional psychoses: an essay
Bergsholm, P. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1101-5 · Cited by 18
Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain
Arango, C., Baeza, I., Bernardo, M., Cañas, F., de Dios, C., Díaz-Marsá, M., García-Portilla, M., Gutiérrez-Rojas, L., Olivares, J., Rico-Villademoros, F., et al. (2019) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2018.03.004 · Cited by 28
How can we best help this patient? Exploring mental health therapists’ reflections on medication-free care for patients with psychosis in Norway
Oedegaard, C., Ruano, A. L., Blindheim, A., Veseth, M., Stige, B., Davidson, L., & Engebretsen, I. (2022) · International Journal of Mental Health Systems · doi:10.1186/s13033-022-00529-8 · Cited by 7
Use of psychiatric medications in schizophrenia and other psychoses in a general population sample
Nykänen, S., Puska, V., Tolonen, J., Salo, H., Isohanni, M. K., Koponen, H., Pirkola, S. P., Penttilä, M., Haapea, M., Moilanen, J. S., et al. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.11.013 · Cited by 14
Study protocol: a randomised controlled trial of cognitive remediation for a national cohort of forensic mental health patients with schizophrenia or schizoaffective disorder
O’Reilly, K., Donohoe, G. J., O’Sullivan, D., Coyle, C., Mullaney, R., O’Connell, P., Maddock, C., Nulty, A., O’Flynn, P., O’Connell, C., et al. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0707-y · Cited by 15
An Integrated Model?
Rodger, J., & Steel, Z. (2016) · Cultural studies of science and medicine · doi:10.1007/978-3-319-24424-2_5 · Cited by 15
Predictive factors of functional outcome in patients with bipolar I disorder: a five-year follow-up
López-Villarreal, A., Sánchez‐Morla, E. M., Jiménez‐López, E., Martínez‐Vizcaíno, V., Aparicio, A. I., Mateo-Sotos, J., Rodríguez–Jiménez, R., Vieta, E., & Santos, J. L. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.140 · Cited by 16
Five-Year Cumulative Exposure to Antipsychotic Medication After First-Episode Psychosis and its Association With 19-Year Outcomes
Bergström, T., Taskila, J. J., Alakare, B., Köngäs‐Saviaro, P., Miettunen, J., & Seikkula, J. (2020) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgaa050 · Cited by 14
Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity
Kimura, H., Kanahara, N., & Iyo, M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113126 · Cited by 16
Tapered discontinuation vs. maintenance therapy of antipsychotic medication in patients with first-episode schizophrenia: Obstacles, findings, and lessons learned in the terminated randomized clinical trial TAILOR
Stürup, A. E., Hjorthøj, C. R., Albert, N., Dolmer, S., Birk, M., Ebdrup, B. H., Eplov, L. F., Jensen, H., Vernal, D. L., Speyer, H., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.910703 · Cited by 14
Switching from risperidone to paliperidone palmitate in schizophrenia: Changes in social functioning and cognitive performance
Tost, M., González-Rodríguez, A., Aguayo, R., Pedrero, A. Á., Montalvo, I., Barbero, J. D., Gabernet, R., Izquierdo, E., Merodio, I., Monreal, J. A., et al. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110619 · Cited by 14
Lifetime use of psychiatric medications and cognition at 43 years of age in schizophrenia in the Northern Finland Birth Cohort 1966
Hulkko, A., Murray, G. K., Moilanen, J. S., Haapea, M., Rannikko, I., Jones, P. B., Barnett, J. H., Huhtaniska, S., Isohanni, M. K., Koponen, H., et al. (2017) · European Psychiatry · doi:10.1016/j.eurpsy.2017.06.004 · Cited by 14
The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia
Davidson, M. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.3/mdavidson · Cited by 15
The pharmacological treatment of schizophrenia: how far have we come?
Rubio, J. M., & Kane, J. M. (2022) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.13 · Cited by 13
“89,90 Altogether, these data questioned whether the benefit of maintenance treatment would dissipate over time or, as has been proposed by some, whether it could have long ‐ term detrimental effects.”
Background
Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium
Koops, S., Allott, K., de Haan, L., Chen, E. Y. H., Hui, C. L. M., Killackey, E. J., Long, M., Moncrieff, J., Sommer, I. E., Stürup, A. E., et al. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad112 · Cited by 13
Time-dependent effect of antipsychotic discontinuation and dose reduction on social functioning and subjective quality of life–a multilevel meta-analysis
Schlier, B., Buck, L., Müller, R., Lincoln, T. M., Bott, A., & Pillny, M. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102291 · Cited by 14
Continuous Dopamine D2 Receptor Blockade and Long-Term Outcome in First-Episode Schizophrenia
Tiihonen, J., Tanskanen, A. J., Solmi, M., Rubio, J. M., Correll, C. U., Kane, J. M., & Taipale, H. T. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240321 · Cited by 14
2012 CCNP Innovations Award Paper: Antipsychotic dosing: found in translation
Remington, G. J., Fervaha, G., Foussias, G., Agid, O., & Turrone, P. (2014) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.130191 · Cited by 13
The longitudinal effect of antipsychotic burden on psychosocial functioning in first-episode psychosis patients: the role of verbal memory
Ballesteros, A., Torres, A. S. S., López-Ilundain, J., Mezquida, G., Lobo, A., González-Pinto, A., Pina-Camacho, L., Corripio, I., Vieta, E., de la Serna, E., et al. (2020) · Psychological Medicine · doi:10.1017/s003329172000080x · Cited by 9
Effect of lithium on suicide and mortality in mood disorders: A systematic review
Börjesson, J., & Gøtzsche, P. C. (2019) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-190058 · Cited by 13
Continuous versus extended antipsychotic dosing in schizophrenia: Less is more
Servonnet, A., Uchida, H., & Samaha, A. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113076 · Cited by 14
Improving psychology students’ attitudes toward people with schizophrenia: A quasi-randomized controlled study.
Magliano, L., Rinaldi, A., Costanzo, R., Leo, R. D., Schioppa, G., Petrillo, M., & Read, J. (2016) · American Journal of Orthopsychiatry · doi:10.1037/ort0000161 · Cited by 13
Implementing gradual, hyperbolic tapering of long-acting injectable antipsychotics by prolonging the inter-dose interval: an in silico modelling study
O’Neill, J. R., Taylor, D. M., & Horowitz, M. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231198463 · Cited by 12
The Factors Affecting the Relationship between Remission Status and Employment in Chronic Schizophrenia Patients
Erim, B. R., Boztaş, M. H., Yıldız, M., & Uygun, E. (2019) · Psychiatry Investigation · doi:10.30773/pi.2019.0087 · Cited by 12
Open Dialogue as a cultural practice - critical perspectives on power obstacles when teaching and enabling this approach in current psychiatry
von Peter, S., Eissing, K., & Saliger, K. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.1063747 · Cited by 12
Attitudes toward and patterns of medication use among people with serious mental illness: There’s more than meets the eye
Asher, M., Roe, D., & Hasson‐Ohayon, I. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1133140 · Cited by 13
Confounding of Antipsychotic Discontinuation Studies by Withdrawal-Related Relapse
Horowitz, M. A., Murray, R. M., & Taylor, D. M. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab146 · Cited by 12
Recovery from psychosis: physical health, antipsychotic medication and the daily dilemmas for mental health nurses
Bressington, D. T., & White, J. (2015) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12249 · Cited by 14
Drug-centred psychopharmacology: a non-diagnostic framework for drug treatment†
Yeomans, D., Moncrieff, J., & Huws, R. (2015) · BJPsych Advances · doi:10.1192/apt.bp.114.013094 · Cited by 12
Diagnostic stability and long-term symptomatic and functional outcomes in first-episode antipsychotic-naïve patients with schizophrenia
Klærke, L. R., Baandrup, L., Fagerlund, B., Ebdrup, B. H., Pantelis, C., Glenthoj, B. Y., & Nielsen, M. Ø. (2019) · European Psychiatry · doi:10.1016/j.eurpsy.2019.07.001 · Cited by 12
Early intervention services, patterns of prescription and rates of discontinuation of antipsychotic treatment in first‐episode psychosis
Catalán, A., García, L., Sánchez-Alonso, S., Gil, P., Díaz‐Marsá, M., Olivares, J. M., Baltanás, T. R., Pérez‐Martín, J., Torres, M. Á. G., Ovejero, S., et al. (2020) · Early Intervention in Psychiatry · doi:10.1111/eip.13098 · Cited by 12
Towards a framework to develop neuroimaging biomarkers of relapse in schizophrenia
Rubio, J. M., Malhotra, A. K., & Kane, J. M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113099 · Cited by 13
Pharmakologische Langzeitbehandlung schizophrener Erkrankungen
Deutschenbaur, L., Lambert, M., Walter, M., Naber, D., & Huber, C. G. (2014) · Der Nervenarzt · doi:10.1007/s00115-013-3807-7 · Cited by 12
IMPACT OF STRESS RESPONSE IN DEVELOPMENT OF FIRST-EPISODE PSYCHOSIS IN SCHIZOPHRENIA: AN OVERVIEW OF SYSTEMATIC REVIEWS
Gajšak, L. R., Gelemanović, A., Kuzman, M. R., & Puljak, L. (2017) · Psychiatria Danubina · doi:10.24869/psyd.2017.14 · Cited by 12
Guidelines for Discontinuation of Antipsychotics in Patients Who Recover From First-Episode Schizophrenia Spectrum Disorders: Derived From the Aggregated Opinions of Asian Network of Early Psychosis Experts and Literature Review
Asian Network of Early Psychosis Writing Group, Hui, C. L. M., Chen, E. Y. H., Verma, S., Tagata, H., Mizuno, M., Liu, C., Takeuchi, H., Kim, S., & Chung, Y. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac002 · Cited by 11
Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis Recurrence
Davidson, M., & Carpenter, W. T. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad145 · Cited by 12
Deprescribing antipsychotics in patients with schizophrenia: findings from a specialized clinic
Nøstdal, A., Hilker, R. W., Halgren, C., Speyer, H., Nielsen, M. Ø., & Nielsen, J. (2024) · Psychological Medicine · doi:10.1017/s0033291724001910 · Cited by 11
Is there compelling evidence that schizophrenia long‐term treatment guidelines should be changed?
Leucht, S. (2018) · World Psychiatry · doi:10.1002/wps.20520 · Cited by 11
The client experience of psychiatric medication: A qualitative study
Lacasse, J. R., Piel, M. H., Lietz, C. A., Rider, A., & Hess, J. Z. (2015) · Social Work in Mental Health · doi:10.1080/15332985.2015.1058312 · Cited by 12
Somatische Morbidität bei psychisch Kranken
Hewer, W., & Schneider, F. W. (2016) · Der Nervenarzt · doi:10.1007/s00115-016-0146-5 · Cited by 11
Das deutsche Forschungsnetz zu psychischen Erkrankungen
Bauer, M., Banaschewski, T., Heinz, A., Kamp‐Becker, I., Meyer‐Lindenberg, A., Padberg, F., Rapp, M. A., Rupprecht, R., Schneider, F. W., Schulze, T. G., et al. (2016) · Der Nervenarzt · doi:10.1007/s00115-016-0169-y · Cited by 12
Adjunctive Treatment of Psychotic Disorders with Micronutrients
Mehl‐Madrona, L., & Mainguy, B. (2017) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2016.0215 · Cited by 11
Medication, hospitalizations and mortality in 5 years after first‐episode psychosis in a Swedish nation‐wide cohort
Strålin, P., & Hetta, J. E. (2018) · Early Intervention in Psychiatry · doi:10.1111/eip.12697 · Cited by 11
Service-user efforts to maintain their wellbeing during and after successful withdrawal from antipsychotic medication
Larsen-Barr, M., & Seymour, F. W. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125321989133 · Cited by 11
Protocol of guided antipsychotic reduction to reach minimum effective dose ( GARMED ) in patients with remitted psychosis based on pragmatic design
Liu, C., Hsieh, M. H., Chien, Y., Liu, C., Lin, Y., Hwang, T., & Hwu, H. (2021) · Early Intervention in Psychiatry · doi:10.1111/eip.13144 · Cited by 11
Medication strategies in first episode psychosis patients: A survey among psychiatrists
Kikkert, M., Veling, W., de Haan, L., Begemann, M., de Koning, M. B., & Sommer, I. E. (2021) · Early Intervention in Psychiatry · doi:10.1111/eip.13138 · Cited by 10
[Functional remission of people with serious mental illness (SMI): psychometric properties of a new ROM-instrument].
Wiersma, D., Visser, E., Bähler, M., Bruggeman, R., Delespaul, P., van der Gaag, M., de Haan, L., Keet, I. P. M., Nijssen, Y. A. M., van Os, J., et al. (2015) · PubMed · Cited by 12
‘Global Mental Health Spreads Like Bush Fire in the Global South’: Efforts to Scale Up Mental Health Services in Low- and Middle-Income Countries
Mills, C., & White, R. G. (2017) · Palgrave Macmillan UK eBooks · doi:10.1057/978-1-137-39510-8_10 · Cited by 11
Paliperidone and pregnancy—an evaluation of the German Embryotox database
Onken, M., Mick, I., & Schaefer, C. (2018) · Archives of Women s Mental Health · doi:10.1007/s00737-018-0828-z · Cited by 11
Recovery without normalisation: It's not necessary to be normal, not even in psychiatry
Chappell, Z., & Jeppsson, S. M. I. (2023) · Clinical Ethics · doi:10.1177/14777509231165880 · Cited by 11
Clinical experiences of guided tapering of antipsychotics for patients with schizophrenia– a case series
Mølgaard, S. N., Nielsen, M. Ø., Roed, K., & Nielsen, J. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05699-y · Cited by 10
Investigating the symptomatic and morphological changes in the brain based on pre and post-treatment: A critical review from clinical to neuroimaging studies on schizophrenia
Chatterjee, I., & Chatterjee, S. (2023) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2023.03.008 · Cited by 11
L’utilisation des thérapies assistées par ordinateur et des jeux vidéo à visée thérapeutique dans les soins de réhabilitation psychosociale chez les sujets souffrant de schizophrénie, revue de la littérature
Brun, G., Verdoux, H., Couhet, G., & Quilès, C. (2018) · L Encéphale · doi:10.1016/j.encep.2017.12.009 · Cited by 10
Should antipsychotic medications for schizophrenia be given for a lifetime? Replication of a naturalistic, long-term, follow-up study of antipsychotic treatment
Glick, I. D., Zamora, D., Kamis, D., & Davis, J. M. (2019) · CNS Spectrums · doi:10.1017/s109285291800144x · Cited by 10
Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first‐episode psychosis cohort
Mas, S., Gassó, P., Rodríguez, N., Cabrera, B., Mezquida, G., Lobo, A., González‐Pinto, A., Parellada, M., Corripio, I., Vieta, E., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13131 · Cited by 10
Return to College After a First Episode of Psychosis
Shinn, A. K., Cawkwell, P. B., Bolton, K. W., Healy, B. C., Karmacharya, R., Yip, A. G., Öngür, D., & Pinder-Amaker, S. (2020) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgaa041 · Cited by 11
What is the evidence for antipsychotic medication and alternative psychosocial interventions for people with acute, non-affective psychosis?
Jauhar, S., & Lawrie, S. M. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00293-5 · Cited by 10
A qualitative exploration of family members’ perspectives on reducing and discontinuing antipsychotic medication
Lewins, A., Morant, N. J., Akther-Robertson, J., Crellin, N. E., Stansfeld, J. L., Smith, R., & Moncrieff, J. (2022) · Journal of Mental Health · doi:10.1080/09638237.2022.2069710 · Cited by 10
Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review
Danborg, P. B., & Gøtzsche, P. C. (2019) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-195063 · Cited by 10
The effects of antipsychotic discontinuation or maintenance on the process of recovery in remitted first-episode psychosis patients – A systematic review and meta-analysis of randomized controlled trials
Béchard, L., Desmeules, C., Bachand, L., Huot‐Lavoie, M., Corbeil, O., Anderson, E. L., Brodeur, S., LeBlanc, A., Demers, M., Lauzier, S., et al. (2024) · European Psychiatry · doi:10.1192/j.eurpsy.2024.5 · Cited by 9
Medisinfrie sykehusposter – et kunnskapsløst tiltak
Røssberg, J. I., Andreassen, O. A., & Ilner, S. O. (2017) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.17.0091 · Cited by 9
Discontinuing Antipsychotic Medication After Remission from First-Episode Psychosis: A Survey of Psychiatrists’ Attitudes in Taiwan
Yen, K., Liu, C., Lin, Y., Chien, Y., Hsieh, M. H., Liu, C., Hwang, T., Liao, W.-H., & Hwu, H. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s339866 · Cited by 9
Need adapted use of medication in the open dialogue approach for psychosis: a descriptive longitudinal cohort study
Bergström, T., Seikkula, J., Köngäs‐Saviaro, P., Taskila, J. J., & Aaltonen, J. (2022) · Psychosis · doi:10.1080/17522439.2022.2134444 · Cited by 9
Drug-free after basal exposure therapy
Hammer, J., Heggdal, D., Lillelien, A., Lilleby, P., & Fosse, R. (2018) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.17.0811 · Cited by 9
An observational study of antipsychotic medication discontinuation in first-episode psychosis: clinical and functional outcomes
MALLA, A. K., Iyer, S. N., Joober, R., THARA, R., Ramachandran, P., Schmitz, N., Taksal, A., Mohan, G., & Margolese, H. C. (2022) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-022-02230-0 · Cited by 8
Factors Associated With Successful Medication Discontinuation After a Randomized Clinical Trial of Relapse Prevention in First-Episode Psychosis
Hui, C. L. M., Honer, W. G., Lee, E. H. M., Chang, W. C., Chan, S. K. W., & Chen, E. Y. H. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3120 · Cited by 9
Antipsychotika
Müller, M. J., & Benkert, O. (2016) · Springer eBooks · doi:10.1007/978-3-662-50333-1_3 · Cited by 9
Improving Community Mental Health Services: The Need for a Paradigm Shif.
Longden, E., Read, J., & Dillon, J. (2016) · PubMed · Cited by 10
Early Medication Discontinuation on Long-term Recovery Outcome in First-Episode Psychosis
Undurraga, J. P., Murru, A., & Vieta, E. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.2993 · Cited by 9
Accepting and Working with Voices
Corstens, D., Escher, S., Romme, M., & Longden, E. (2018) · Wiley eBooks · doi:10.1002/9781118585948.ch24 · Cited by 9
Helping people to discontinue antipsychotics: if, when and how
Moncrieff, J., & Horowitz, M. A. (2025) · Schizophrenia · doi:10.1038/s41537-025-00695-x · Cited by 9
There Is No Cure for Existence: On the Medicalization of Psychological Distress
Albarracín, D., Ducousso‐Lacaze, A., Cohen, D., Gonon, F., Keller, P.-H., & Minard, M. (2015) · Ethical Human Psychology and Psychiatry · doi:10.1891/1559-4343.17.3.149 · Cited by 8
Perspective on medication decisions following remission from first-episode psychosis
Hui, C. L. M., Lam, B. S. T., Lee, E. H. M., Chan, S. K. W., Chang, W. C., Suen, Y. N., & Chen, E. Y. H. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.02.007 · Cited by 10
Antipsychotic discontinuation: mind the patient and the real-world evidence
Luykx, J. J., & Tiihonen, J. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00159-0 · Cited by 8
How important are informed consent, informed choice, and patient-doctor relationships, when prescribing antipsychotic medication?
Read, J. (2022) · Journal of Mental Health · doi:10.1080/09638237.2022.2069708 · Cited by 9
Community Health Workers: a Resource to Support Antipsychotic Medication Adherence
Allen, C. G., Sugarman, M. A., & Wennerstrom, A. (2016) · The Journal of Behavioral Health Services & Research · doi:10.1007/s11414-016-9515-x · Cited by 8
A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: rationale, study design and baseline data of the COMPARE trial
Law, H., Carter, L., Sellers, R., Emsley, R., Byrne, R. E., Davies, L. M., French, P., Haddad, P. M., Pitt, E., Pyle, M., et al. (2017) · Psychosis · doi:10.1080/17522439.2017.1316302 · Cited by 8
Trends in Schizophrenia Diagnosis and Treatment
Gäebel, W., Riesbeck, M., Larach, V. W., Falkai, P., & Zielasek, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-70554-5_35 · Cited by 8
Neurocognition, functional outcome, and quality of life in remitted and non-remitted schizophrenia: A comparison with euthymic bipolar I disorder and a control group.
Jiménez‐López, E., Villanueva-Romero, C. M., Sánchez‐Morla, E. M., Martínez‐Vizcaíno, V., Ortiz, M., Rodríguez–Jiménez, R., Vieta, E., & Santos, J. L. (2022) · Schizophrenia Research · doi:10.1016/j.schres.2021.12.038 · Cited by 9
Schizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 9
Using in silico methods to determine optimal tapering regimens for decanoate-based long-acting injectable psychosis drugs
O’Neill, J. R., Taylor, D. M., & Horowitz, M. A. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241272790 · Cited by 7
Prevalence of autism in first-episode psychosis in two Hong Kong teaching hospitals
Kwok, T. S., Chan, M. M. Y., Mo, F. Y. M., Hung, S., Leung, P. W. L., Lai, K. Y. C., & Shea, C. K. (2024) · Autism · doi:10.1177/13623613241259062 · Cited by 7
Do antipsychotics work in people with schizophrenia? A review of outcomes and effect sizes
Correll, C. U. (2025) · CNS Spectrums · doi:10.1017/s1092852925100461 · Cited by 7
Revisitando Whitaker: psicofármacos e cuidado em Saúde Mental na Atenção Primária à Saúde
Secco, A. C., & Tesser, C. D. (2023) · Saúde em Debate · doi:10.1590/0103-1104202313916 · Cited by 9
Early interventions for prodromal stage of psychosis
Bošnjak, D., Kekin, I., Hew, J., & Kuzman, M. R. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012236 · Cited by 7
Cognitive, Work and Social Outcomes in Fully Recovered First-Episode Schizophrenia: On and Off Antipsychotic Medication
Fu, S., Czajkowski, N. O., & Torgalsbøen, A. (2019) · Psychiatry · doi:10.1080/00332747.2018.1550735 · Cited by 7
Cognitive Enhancement in Schizophrenia and Related Disorders
Keshavan, M. S., & Eack, S. M. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108163682 · Cited by 7
The Predicted Long-Term Benefits of Ensuring Timely Treatment and Medication Adherence in Early Schizophrenia
Horvitz-Lennon, M. V., Predmore, Z., Orr, P., Hanson, M., Hillestad, R. J., Durkin, M., Khoury, A. C. E., & Mattke, S. (2019) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-019-00990-7 · Cited by 7
Antipsychotic maintenance treatment versus dose reduction: how the story continues
Sommer, I. E., Horowitz, M. A., Allott, K., Speyer, H., & Begemann, M. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00230-9 · Cited by 7
Chronic Use of Antipsychotics in Schizophrenia: Are We Asking the Right Question?
Rubio, J. M., & Pérez-Rodríguez, M. M. (2022) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgac059 · Cited by 7
Radical psychotic doubt and epistemology
Jeppsson, S. M. I. (2022) · Philosophical Psychology · doi:10.1080/09515089.2022.2147815 · Cited by 7
The biological paradigm of psychosis in crisis: A Kuhnian analysis
Pearson, M., Rennick‐Egglestone, S., & Winship, G. (2023) · Nursing Philosophy · doi:10.1111/nup.12418 · Cited by 10

Authors: Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. J.
Affiliations: University Medical Center Groningen (NL)
Corresponding author: Wunderink, Lex
ORCID: Wunderink, Lex
Sytema, Sjoerd
Venue: JAMA Psychiatry
Publisher: American Medical Association (AMA)
Published: 2013-09-01
Volume: 70
Issue: 9
Pages: 913
ISSN: 2168-622X (ISSN-L)
DOI: 10.1001/jamapsychiatry.2013.19
OpenAlex: W2125616168
Cited by: 567
References: 24
Citations by year: 2026: 17 · 2025: 27 · 2024: 31 · 2023: 39 · 2022: 37 · 2021: 47 · 2020: 42 · 2019: 71 · 2018: 59 · 2017: 43 · 2016: 65 · 2015: 42 · 2014: 36 · 2013: 8
FWCI: 35.58
Type: journal article
Language: en
Open access: closed
Locations: JAMA Psychiatry (publishedVersion)
PubMed (publishedVersion)
University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
Keywords: first-episode psychosis, remission, antipsychotic dose reduction, antipsychotic discontinuation, long-term antipsychotic treatment, long-term recovery, functional remission, symptom remission, relapse
MeSH terms: Adult, Female, Follow-Up Studies, Humans, Long-Term Care, Male, Psychotic Disorders, Recurrence, Remission Induction, Antipsychotic Agents, Treatment Outcome, Age of Onset, Young Adult, Maintenance Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy: Long-term Follow-up of a 2-Year Randomized Clinical Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks